Dupixent (dupilumab) is a prescription medication that treats several conditions driven by inflammation in the body. The drug works by blocking specific proteins that trigger allergic and inflammatory responses. Originally approved by the FDA in 2017, Dupixent has become a treatment option for moderate-to-severe atopic dermatitis (eczema), moderate-to-severe asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.
Learn About Paying Your FGUA Bill Online →
The medication comes as a pre-filled pen or syringe for injection. Most patients start with an initial dose, then receive maintenance injections either every two weeks or every four weeks, depending on their condition and body weight. Because Dupixent requires ongoing injections and typically costs between $3,000 and $4,000 per month without insurance, whether Medicare covers it significantly affects affordability for older adults and certain younger people with disabilities.
Medicare's coverage of Dupixent is not automatic or universal across all situations. The program has specific rules about which conditions warrant coverage, which parts of Medicare might pay for it, and what documentation doctors must provide. Understanding these rules helps people know what to expect when discussing Dupixent with their healthcare provider.
Takeaway: Dupixent is an expensive injectable medication for inflammatory conditions. Medicare may help with costs, but coverage depends on specific circumstances. Knowing how Medicare evaluates Dupixent requests gives you context for conversations with your doctor.
Medicare Part B covers injectable drugs administered in a doctor's office or outpatient clinic setting. Since Dupixent is typically given as an injection by healthcare professionals or taught for self-injection under medical supervision, Part B generally covers the medication itself when medically necessary. This means Medicare pays for the actual Dupixent drug, usually after you meet your Part B deductible ($240 in 2024).
Free Guide to Pay by Plate Illinois Billing →
However, Part B coverage requires that the medication be prescribed by a physician and deemed medically necessary for treating your specific condition. The doctor's records must support that you have one of the approved conditions and that Dupixent is an appropriate treatment option. Medicare's contractors review requests to confirm medical necessity, though most standard uses of Dupixent meet this standard once approved conditions are documented.
After meeting your deductible, you typically pay 20% coinsurance for the drug itself. If you receive Dupixent in a hospital outpatient department rather than a doctor's office, slightly different rules may apply, and your costs could be different. Many people find that their out-of-pocket costs for Dupixent through Part B remain substantial even with coverage, which is why supplemental insurance or other cost-reduction programs matter.
Important distinction: Part B covers the drug administration and the medication when given in a clinical setting. It does not cover routine office visit fees separately for the injection appointment, though those visits may be covered under standard Part B visit coverage rules.
Takeaway: Medicare Part B typically covers Dupixent injections given in medical settings once your doctor documents medical necessity. You pay the Part B deductible and 20% coinsurance, meaning substantial out-of-pocket costs remain even with Medicare coverage.
Medicare covers Dupixent primarily for atopic dermatitis (eczema) when it is moderate to severe and has not responded adequately to topical treatments. Atopic dermatitis is a chronic skin condition causing intense itching, inflammation, and skin barrier dysfunction. Documentation must show that the condition significantly impacts the person's quality of life and that other treatments have been tried first.
Free Guide to Mold Removal Methods for Walls →
For asthma, Medicare covers Dupixent when the asthma is moderate to severe, eosinophilic (involving high levels of eosinophils, a type of white blood cell), or allergic in nature. Your doctor must document that your asthma is difficult to control with standard medications and that you meet specific clinical criteria. The medical record should show lung function tests and documentation of asthma severity.
Chronic rhinosinusitis with nasal polyps represents another condition Medicare may cover Dupixent for. This involves chronic sinus inflammation with growths in the nasal passages. Typically, documentation includes imaging (CT scan) showing polyps and evidence that standard treatments have not worked.
Eosinophilic esophagitis is the newest indication on Medicare's coverage list. This rare condition involves excessive eosinophils in the esophagus, causing swallowing difficulty and food impaction. Diagnosis requires endoscopy with biopsy showing eosinophil levels above a specific threshold.
Off-label uses (treating conditions Dupixent is not FDA-approved for) may sometimes be covered on a case-by-case basis, but this requires strong medical justification and documentation. Medicare contractors evaluate each request individually.
Takeaway: Medicare recognizes four main conditions for Dupixent coverage: moderate-severe atopic dermatitis, certain types of asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Your doctor must document your specific condition and prior treatment attempts.
Before Medicare pays for Dupixent, your doctor's office typically must obtain prior authorization—approval from Medicare's contractor for your region confirming the medication is medically necessary for your situation. This is not a quick process; it usually takes 3-10 business days, though urgent requests may be expedited.
How to Delete Your Fitbit Account Guide →
The authorization request includes your medical records, documentation of your diagnosis, details about other treatments you've tried, current test results, and your doctor's clinical justification for Dupixent. Medicare's medical reviewers examine this information against current clinical guidelines and coverage policies. They verify that your condition matches approved diagnoses and that you've had appropriate prior treatment attempts.
Your doctor's office handles submitting the prior authorization request—you don't typically do this yourself, though you can ask your doctor's staff about the status. If Medicare denies the authorization, your doctor's office receives a letter explaining the reason. Common denials occur when medical records don't clearly document the condition, when prior treatments weren't given adequate time to work, or when documentation doesn't meet current clinical standards.
If denied, your doctor can appeal the decision by submitting additional information or clarifying documentation. Many initial denials are overturned on appeal when the doctor provides more detailed clinical information. You have the right to request the appeal even if your doctor doesn't initially pursue it.
Some people do not need prior authorization if their doctor can demonstrate clear medical necessity with excellent documentation. However, this is uncommon; most Dupixent prescriptions require authorization.
Takeaway: Your doctor must request prior authorization before Medicare typically covers Dupixent. This takes about a week and involves submitting medical records showing your condition and prior treatment attempts. Denials can be appealed with additional documentation.
If you take Dupixent through a different route than Medicare Part B covers—such as self-injecting at home using a prescription filled through a pharmacy—your Medicare Part D drug plan may cover it instead. Part D is prescription drug coverage for medications filled at retail or mail-order pharmacies. Dupixent typically falls into Part D's specialty tier because it is an expensive, self-injected biologic drug.
Learn How to Grow Sweet Corn at Home →
Most Medicare Part D plans do cover Dupixent, but your specific out-of-pocket costs depend on your plan's formulary and your stage in the benefit year. In 2024, your Part D costs include a deductible (up to $545), then copay amounts in the initial coverage stage, then a coverage gap ("donut hole"), and finally catastrophic coverage. Dupixent's high cost means you'll reach the coverage gap quickly, where you pay a larger percentage of the drug's cost yourself.
Many specialty pharmacies work directly with manufacturers to administer Dupixent programs that reduce costs. The Dupixent Savings Card, for example, may lower your out-of-pocket costs to $0-$50 per month if you're commercially insured or have Part D, depending on your plan. This program is separate from Medicare but can work alongside your Part D coverage.
Coordination between Part B and Part D matters. If your
This guide is for general information only and is not medical, financial, legal, or other professional advice. For decisions specific to your situation, consult a qualified professional. See our Editorial Policy.